Salmeterol's extreme β2 selectivity is due to residues in both extracellular loops and transmembrane domains

Molecular Pharmacology

Volumn 87, Issue 1, 2015, Pages 103-120

  Baker, Jillian G ^a   Proudman, Richard G W ^a   Hill, Stephen J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; ADRENALIN; AMINO ACID; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CLENBUTEROL; CYCLIC AMP; FENOTEROL; FORMOTEROL; ISOPRENALINE; LIGAND; SALBUTAMOL; SALMETEROL; THROMBOPLASTIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; SALMETEROL XINAFOATE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CHO CELL LINE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FEMALE; LIPOPHILICITY; MUTAGENESIS; NONHUMAN; POINT MUTATION; WHOLE CELL; ANALOGS AND DERIVATIVES; ANIMAL; BINDING SITE; CHEMISTRY; CRICETULUS; DRUG EFFECTS; GENETICS; HAMSTER; HUMAN; METABOLISM;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; AMINO ACIDS; ANIMALS; BINDING SITES; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; POINT MUTATION; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; SALMETEROL XINAFOATE;

EID: 84919908780     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.095364     Document Type: Article

References (41)

1. Anderson GP, Lindén A, and Rabe KF (1994) Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 7:569-578.
2. Baker JG (2005) The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol 144:317-322.
3. Baker JG (2010) The selectivity of β -adrenoceptor agonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol 160:1048-1061.
4. Baker JG, Proudman RG, and Hill SJ (2014) Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor. Mol Pharmacol 85:811-829.
5. Ball DI, Brittain RT, Coleman RA, Denyer LH, Jack D, Johnson M, Lunts LH, Nials AT, Sheldrick KE, and Skidmore IF (1991) Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 104:665-671.
6. Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Farr D, Fozard JR, Leighton-Davies JR, Lewis CA, and McEvoy L, et al. (2006) In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 317:762-770.
7. Bradshaw J, Brittain RT, Coleman RA, Jack D, Kennedy I, Lunts LHC, and Skidmore IF (1987) The design of salmeterol, a long-acting selective b2-adrenoceptor agonist. Br J Pharmacol 92:590P.
8. Brittain RT, Farmer JB, Jack D, Martin LE, and Simpson WT (1968) Alpha-[(t-butylamino)methyl]-4-hydroxy-m-xylene-alpha 1,alpha 3-diol (AH.3365): a selective beta-adrenergic stimulant. Nature 219:862-863.
9. Cazzola M, Page CP, Calzetta L, and Matera MG (2012) Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 64:450-504.
10. Clark RB, Allal C, Friedman J, Johnson M, and Barber R (1996) Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite. Mol Pharmacol 49 :182-189.
11. Coleman RA, Johnson M, Nials AT, and Vardey CJ (1996) Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists. Trends Pharmacol Sci 17:324-330.
12. Dixon RA, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, Frielle T, Bolanowski MA, Bennett CD, Rands E, and Diehl RE, et al. (1986) Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 321:75-79.
13. Dixon RA, Sigal IS, Candelore MR, Register RB, Scattergood W, Rands E, and Strader CD (1987a) Structural features required for ligand binding to the betaadrenergic receptor. EMBO J 6:3269-3275.
14. Dixon RA, Sigal IS, Rands E, Register RB, Candelore MR, Blake AD, and Strader CD (1987b) Ligand binding to the beta-adrenergic receptor involves its rhodopsin-like core. Nature 326:73-77.
15. Dohlman HG, Caron MG, Strader CD, Amlaiky N, and Lefkowitz RJ (1988) Identification and sequence of a binding site peptide of the beta 2-adrenergic receptor. Biochemistry 27:1813-1817.
16. Frielle T, Daniel KW, Caron MG, and Lefkowitz RJ (1988) Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors. Proc Natl Acad Sci USA 85:9494-9498.
17. Green SA, Rathz DA, Schuster AJ, and Liggett SB (2001) The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol 421:141-147.
18. Green SA, Spasoff AP, Coleman RA, Johnson M, and Liggett SB (1996) Sustained activation of a G protein-coupled receptor via "anchored" agonist binding: molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem 271:24029-24035.
19. Hartley D, Jack D, Lunts LH, and Ritchie AC (1968) New class of selective stimulants of beta-adrenergic receptors. Nature 219:861-862.
20. Isogaya M, Sugimoto Y, Tanimura R, Tanaka R, Kikkawa H, Nagao T, and Kurose H (1999) Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtypeselective agonists. Mol Pharmacol 56:875-885.
21. Isogaya M, Yamagiwa Y, Fujita S, Sugimoto Y, Nagao T, and Kurose H (1998)
22. Identification of a key amino acid of the beta2-adrenergic receptor for high affinity binding of salmeterol. Mol Pharmacol 54:616-622.
23. Jack D (1991) The 1990 Lilly Prize Lecture: a way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other beta-adrenoceptor agonists. Br J Clin Pharmacol 31:501-514.
24. Johnson M (1995) Salmeterol. Med Res Rev 15:225-257.
25. Katritch V, Cherezov V, and Stevens RC (2013) Structure-function of the G proteincoupled receptor superfamily. Annu Rev Pharmacol Toxicol 53:531-556.
26. Kew KM, Dias S, and Cates CJ (2014) Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev 3:CD010844.
27. Kikkawa H, Isogaya M, Nagao T, and Kurose H (1998) The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. Mol Pharmacol 53:128-134.
28. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
29. Marullo S, Emorine LJ, Strosberg AD, and Delavier-Klutchko C (1990) Selective binding of ligands to beta 1, beta 2 or chimeric beta 1/beta 2-adrenergic receptors involves multiple subsites. EMBO J 9:1471-1476.
30. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS, et al. (2001) Structure of a nanobodystabilized active state of the b(2) adrenoceptor. Nature 469:175-180. doi: 10.1038/ nature09648.
31. Rhodes DG, Newton R, Butler R, and Herbette L (1992) Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers. Mol Pharmacol 42:596-602.
32. Rong Y, Arbabian M, Thiriot DS, Seibold A, Clark RB, and Ruoho AE (1999) Probing the salmeterol binding site on the beta 2-adrenergic receptor using a novel photoaffinity ligand, [(125)I]iodoazidosalmeterol. Biochemistry 38:11278-11286.
33. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, Rasmussen SGF, Choi HJ, Devree BT, and Sunahara RK, et al. (2011) Structure and function of an irreversible agonist-β(2) adrenoceptor complex. Nature 469:236-240.
34. Strader CD, Sigal IS, Register RB, Candelore MR, Rands E, and Dixon RA (1987) Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc Natl Acad Sci USA 84:4384-4388.
35. Sykes DA, Parry C, Reilly J, Wright P, Fairhurst RA, and Charlton SJ (2014) Observed drug-receptor association rates are governed by membrane affinity: the importance of establishing "micro-pharmacokinetic/pharmacodynamic relationships" at the β2-adrenoceptor. Mol Pharmacol 85:608-617.
36. Ullman A and Svedmyr N (1988) Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 43:674-678.
37. Vauquelin G (2010) Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin Drug Discov 5: 927-941.
38. Vauquelin G and Charlton SJ (2010) Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 161:488-508.
39. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, and Babu MM (2013) Molecular signatures of G-protein-coupled receptors. Nature 494: 185-194.
40. Waldeck B (2002) Beta-adrenoceptor agonists and asthma-100 years of development. Eur J Pharmacol 445:1-12.
41. Wong S.K. Slaughter C. Ruoho A.E. Ross E.M. 1988 The catecholamine binding site of the beta-adrenergic receptor is formed by juxtaposed membrane-spanning domains. J Biol Chem 263 7925-7928